Re: Oryzon Genomics (ORY)
Saludos
Maes et al. highlighted therapeutic potential of ORY-1001 and checkpoint inhibitors for the treatment of melanoma [78]. After co-treatment with ORY-1001 and the anti-PD1 antibody for 22 days, significant tumor growth inhibition (TGI) was achieved, 54% higher than that of the anti-PD1 antibody-treated group.
Treatment with iadademstat and the checkpoint inhibitor anti-Pd1 monoclonal antibody was well tolerated. By Day 15, treatment with the anti-Pd1 antibody alone or in combo with iadademstat reduced tumor growth by 45% and 65% relative to vehicle controls. Control animals were sacrificed by day 19 due to progression. By day 22, 54% reduction was achieved in the animals treated with the combination compared to the animals treated with the anti-Pd1 antibody alone.
Nevertheless, our data suggest that overexpression of LSD1 cannot permanently overcome pathological tau.
Thus, we conclude that MAO-B has a regulatory effect on intraneuronal Aβ levels, presumably mediated by γ-secretase. In addition, we envision the γ-secretase/MAO-B association as a potential target for pharmaceutical intervention of AD.
tau hyperphosphorylation may be related to accumulated Abeta.
HIPPOCAMPAL LEVEL OF LSD1 CORRELATES WITH INTRACELLULAR AMYLOID-BETA LOAD, INFLAMMATION, NEURODEGENERATION AND COGNITIVE DECLINE IN AN AD-LIKE RAT MODEL
.These results demonstrated that intraneuronal Aβ accumulation is sufficient to disrupt LSD1 expression at the early stages of the AD-like amyloid pathology, before β-Amyloid plaques formation. Consequently, the increased expression of LSD1 leads to an upregulation in the pro-inflammatory response showing a functional link between the excessive inflammatory status and epigenetic regulation of the inflammatory response by LSD1. Additionally, the dysregulation in LSD1 may contribute to a decline in cognitive functions at late stages (18 months) of the hemizygous transgenic rats, pointing LSD1 as a good candidate for early clinical manipulation.
Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1
https://www.mdpi.com/2072-6694/11/12/2027/htm